60 cholesterol-lowering drug trials. 323,950 people. Statins. PCSK9 inhibitors. Ezetimibe. Every drug class. Every dose.
Mortality is the only endpoint that matters. Not LDL levels. Not cholesterol panels. Not relative risk percentages on a drug label. Did the person live or die.
https://x.com/markkaplan20/status/2070689792807821792
AND
Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis
Big Pharma will not like this message!